Oral Semaglutide: The Tablet That Actually Exists

Oral semaglutide is real, approved and sold as Rybelsus. That makes it the exception in a market full of oral peptide claims that are not — and how it manages the trick is genuinely interesting engineering.

The problem it had to solve

The digestive system exists to break peptides down. Stomach acid, pepsin, trypsin, chymotrypsin and brush-border peptidases all degrade them, and the intestinal wall is a poor route for large, charged molecules. Unmodified peptide bioavailability by mouth is typically well under 1%.

Research into oral GLP-1 delivery has explored elaborate approaches — lipid-based formulations combined with enteric capsules among them — precisely because none of this is straightforward.

How Rybelsus works

It is co-formulated with SNAC — sodium N-(8-[2-hydroxybenzoyl] amino) caprylate — an absorption enhancer. SNAC does two things in the stomach: it locally raises pH, protecting semaglutide from acid and pepsin, and it transiently promotes absorption across the gastric mucosa.

Why the dosing rules are strict

These are not conservative suggestions. Adherence to them substantially determines how much drug is absorbed, and bioavailability remains low and variable even when followed exactly — which is why the oral doses are so much larger than the injectable ones.

Dose comparison

What the obesity trials found

A 2025 New England Journal of Medicine trial tested oral semaglutide at 25 mg in adults with overweight or obesity, and the OASIS 2 randomised clinical trial, published in JAMA Internal Medicine, studied an East Asian population with or without type 2 diabetes.

• Clinically meaningful weight reduction was demonstrated at the higher oral doses.

• The adverse event profile mirrors injectable semaglutide — gastrointestinal effects dominate.

• Higher oral doses than the diabetes indication were required for the obesity effect.

• Adherence to the dosing rules is a real-world variable trials control for and daily life does not.

Oral semaglutide versus the alternatives

The small-molecule approach sidesteps the problem rather than solving it. Orforglipron is not a peptide, so digestive proteases do not act on it. That is why oral tirzepatide does not exist while oral semaglutide does — and why the next generation of oral GLP-1 drugs is likely not to be peptides at all. See the oral tirzepatide guide.

What this means for oral peptide claims generally

Rybelsus is proof that oral peptide delivery is possible. It is also a demonstration of what it costs: a purpose-built absorption enhancer, a specific absorption site, strict dosing conditions, roughly hundredfold dose inflation, and a full clinical programme.

An oral peptide product without those things has not solved the problem. See the oral peptides guide, BPC-157 capsules and sermorelin tablets.